- •PROGRESS IN BRAIN RESEARCH
- •List of Contributors
- •Preface
- •Epidemiology of primary glaucoma: prevalence, incidence, and blinding effects
- •Introduction
- •Prevalence of glaucoma
- •PAC suspect
- •PACG
- •Incidence of glaucoma
- •Blinding effects of glaucoma
- •Abbreviations
- •Acknowledgment
- •References
- •Predictive models to estimate the risk of glaucoma development and progression
- •Risk assessment in ocular hypertension and glaucoma
- •Risk factors for glaucoma development
- •Intraocular pressure
- •Corneal thickness
- •Cup/disc ratio and pattern standard deviation
- •The need for predictive models
- •Predictive models for glaucoma development
- •Predictive models for glaucoma progression
- •Limitations of predictive models
- •References
- •Intraocular pressure and central corneal thickness
- •Main text
- •References
- •Angle-closure: risk factors, diagnosis and treatment
- •Introduction
- •Mechanism
- •Other causes of angle closure
- •Risk factors
- •Age and gender
- •Ethnicity
- •Ocular biometry
- •Genetics
- •Diagnosis
- •Acute primary angle closure
- •Angle assessment in angle closure
- •Gonioscopy technique
- •Ultrasound biomicroscopy (UBM)
- •Scanning peripheral anterior chamber depth analyzer (SPAC)
- •Management
- •Acute primary angle closure
- •Medical therapy
- •Argon laser peripheral iridoplasty (ALPI)
- •Laser peripheral iridotomy (PI)
- •Lens extraction
- •Monitoring for subsequent IOP rise in eyes with APAC
- •Fellow eye of APAC
- •Chronic primary angle-closure glaucoma (CACG)
- •Laser peripheral iridotomy
- •Laser iridoplasty
- •Medical therapy
- •Trabeculectomy
- •Lens extraction
- •Combined lens extraction and trabeculectomy surgery
- •Goniosynechialysis
- •Summary
- •List of abbreviations
- •References
- •Early diagnosis in glaucoma
- •Introduction
- •History and examination
- •Quantitative tests and the diagnostic process
- •Pretest probability
- •Test validity
- •Diagnostic test performance
- •Posttest probability
- •Combing test results
- •Selective tests of visual function
- •Early glaucoma diagnosis from quantitative test results
- •Progression to make a diagnosis
- •Conclusions
- •Abbreviations
- •References
- •Monitoring glaucoma progression
- •Introduction
- •Monitoring structural damage progression
- •Monitoring functional damage progression
- •Abbreviations
- •References
- •Standard automated perimetry and algorithms for monitoring glaucoma progression
- •Standard automated perimetry
- •Global indices
- •HFA: MD, SF, PSD, CPSD
- •Octopus indices: MD, SF, CLV
- •OCTOPUS seven-in-one report (Fig. 2)
- •SAP VF assessment: full-threshold strategy
- •SAP VF defects assessment: OHTS criteria
- •SAP VF defects assessment: AGIS criteria
- •SAP VF defects assessment: CIGTS
- •Fastpac
- •Swedish interactive threshold algorithm
- •SAP VF assessment: the glaucoma staging system
- •SAP: interocular asymmetries in OHTS
- •SAP, VF progression
- •SAP: the relationship to other functional and structural diagnostic tests in glaucoma
- •SAP, FDP-Matrix
- •SAP, SWAP, HPRP, FDT
- •SAP: the relationship between function and structure
- •SAP, confocal scanning laser ophthalmoscopy, SLP-VCC
- •SAP, optical coherence tomography
- •SAP and functional magnetic resonance imaging
- •References
- •Introduction
- •Retinal ganglion cells: anatomy and function
- •Is glaucoma damage selective for any subgroup of RGCs?
- •Segregation
- •Isolation
- •FDT: rationale and perimetric techniques
- •SWAP: rationale and perimetric techniques
- •FDT: clinical data
- •SWAP: clinical data
- •Clinical data comparing FDT and SWAP
- •Conclusions
- •References
- •Scanning laser polarimetry and confocal scanning laser ophthalmoscopy: technical notes on their use in glaucoma
- •The GDx scanning laser polarimeter
- •Serial analysis
- •Limits
- •The Heidelberg retinal tomograph
- •Limits
- •Conclusions
- •References
- •The role of OCT in glaucoma management
- •Introduction
- •How OCT works
- •How OCT is performed
- •Evaluation of RNFL thickness
- •Evaluation of optic disc
- •OCT in glaucoma management
- •New perspective
- •Abbreviations
- •References
- •Introduction
- •Technology
- •Visual stimulation
- •Reproducibility and habituation of RFonh
- •Retinal neural activity as assessed from the electroretinogram (ERG)
- •The Parvo (P)- and Magno (M)-cellular pathways
- •Physiology
- •Magnitude and time course of RFonh in humans
- •Varying the parameters of the stimulus on RFonh
- •Luminance versus chromatic modulation
- •Frequency
- •Effect of pattern stimulation
- •Neurovascular coupling in humans
- •Clinical application
- •RFonh in OHT and glaucoma patients
- •Discussion
- •FLDF and neurovascular coupling in humans
- •Comments on clinical application of FLDF in glaucoma
- •Conclusions and futures directions
- •Acknowledgements
- •References
- •Advances in neuroimaging of the visual pathways and their use in glaucoma
- •Introduction
- •Conventional MR imaging and the visual pathways
- •Diffusion MR imaging
- •Functional MR imaging
- •Proton MR spectroscopy
- •References
- •Primary open angle glaucoma: an overview on medical therapy
- •Introduction
- •When to treat
- •Whom to treat
- •Genetics
- •Race
- •Ocular and systemic abnormalities
- •Tonometry and pachymetry
- •How to treat
- •Beta-blockers
- •Prostaglandins
- •Alpha-agonists
- •Carbonic anhydrase inhibitors (CAIs)
- •Myotics
- •Fixed combinations
- •References
- •The treatment of normal-tension glaucoma
- •Introduction
- •Epidemiology
- •Clinical features
- •Optic disk
- •Central corneal thickness
- •Disease course
- •Risk factors
- •Intraocular pressure
- •Local vascular factors
- •Immune mechanisms
- •Differential diagnosis
- •Diagnostic evaluation
- •Therapy
- •IOP reduction
- •Systemic medications
- •Neuroprotection
- •Noncompliance
- •Genetics of NTG
- •Abbreviations
- •References
- •The management of exfoliative glaucoma
- •Introduction
- •Epidemiology
- •Ocular and systemic associations
- •Ocular associations
- •Systemic associations
- •Pathogenesis of exfoliation syndrome
- •Mechanisms of glaucoma development
- •Management
- •Medical therapy
- •Laser surgery
- •Operative surgery
- •Future treatment of exfoliation syndrome and exfoliative glaucoma
- •Treatment directed at exfoliation material
- •References
- •Laser therapies for glaucoma: new frontiers
- •Background
- •Laser iridotomy
- •Indications
- •Contraindications
- •Patient preparation
- •Technique
- •Nd:YAG laser iridectomy
- •Argon laser iridectomy
- •Complications
- •LASER trabeculoplasty
- •Treatment technique
- •Mechanism of action
- •Indications for treatment
- •Contraindications to treatment
- •Patient preparation and postoperative follow-up
- •Complications of the treatment
- •Selective laser trabeculoplasty
- •Results
- •LASER iridoplasty
- •Indications
- •Contraindications
- •Treatment technique
- •Complications
- •LASER cyclophotocoagulation
- •Introduction
- •Indications and contraindications
- •Patient preparation
- •Transpupillary cyclophotocoagulation
- •Endoscopic cyclophotocoagulation
- •Transscleral cyclophotocoagulation
- •Transscleral noncontact cyclophotocoagulation
- •Transscleral contact cyclophotocoagulation
- •Complications
- •Excimer laser trabeculotomy
- •References
- •Modulation of wound healing during and after glaucoma surgery
- •The process of wound healing
- •Using surgical and anatomical principles to modify therapy
- •Growth factors
- •Cellular proliferation and vascularization
- •Cell motility, matrix contraction and synthesis
- •Drug delivery
- •Future directions: total scarring control and tissue regeneration
- •Acknowledgments
- •References
- •Surgical alternative to trabeculectomy
- •Introduction
- •Deep sclerectomy
- •Viscocanalostomy
- •Conclusions
- •References
- •Modern aqueous shunt implantation: future challenges
- •Background
- •Current shunts and factors affecting their function
- •Shunt-related factors
- •Surface area
- •Plate material
- •Valved versus non-valved
- •Commercially available devices
- •Comparative studies
- •Patient and ocular factors
- •Severity of glaucoma damage
- •Tolerance of topical ocular hypotensive medications
- •Aqueous hyposecretion
- •Previous ocular surgery
- •Scleral thinning
- •Patient cooperation for and tolerance of potential slit-lamp interventions
- •Future challenges
- •Predictability
- •Cataract formation
- •The long-term effect on the cornea
- •References
- •Model systems for experimental studies: retinal ganglion cells in culture
- •Mixed RGCs in culture
- •Retinal explants
- •Glial cultures
- •RGC-5 cells
- •Differentiation of RGC-5 cells
- •RGC-5 cell neurites
- •Advantages and disadvantages of culture models
- •References
- •Rat models for glaucoma research
- •Rat models for glaucoma research
- •Use of animal models for POAG
- •Suitability of the rat for models of optic nerve damage in POAG
- •Methods for measuring IOP in rats
- •General considerations for measuring IOP in rats
- •Assessing optic nerve and retina damage
- •Experimental methods of producing elevated IOP
- •Laser treatment of limbal tissues
- •Episcleral vein cautery
- •Conclusions
- •Abbreviations
- •Acknowledgements
- •References
- •Mouse genetic models: an ideal system for understanding glaucomatous neurodegeneration and neuroprotection
- •Introduction
- •The mouse as a model system
- •Mice are suitable models for studying IOP elevation in glaucoma
- •Tools for glaucoma research
- •Accurate IOP measurements are fundamental to the study of glaucoma
- •The future of IOP assessment
- •Assessment of RGC function
- •Mouse models of glaucoma
- •Primary open-angle glaucoma
- •MYOC
- •OPTN
- •Strategies for developing new models of POAG
- •Developmental glaucoma
- •Pigmentary glaucoma
- •Experimentally induced models of glaucoma
- •Mouse models to characterize processes involved in glaucomatous neurodegeneration
- •Similar patterns of glaucomatous damage occur in humans and mice
- •The lamina cribrosa is an important site of early glaucomatous damage
- •An insult occurs to the axons of RGCs within the lamina in glaucoma
- •What is the nature of the insult at the lamina?
- •Other changes occur in the retina in glaucoma
- •PERG and complement
- •Using mouse models to develop neuroprotective strategies
- •Somal protection
- •Axonal protection
- •Erythropoietin administration
- •Radiation-based treatment
- •References
- •Clinical trials in neuroprotection
- •Introduction
- •Methods of clinical studies
- •Issues in the design and conduct of clinical trials
- •Clinical trials of neuroprotection
- •Clinical trials of neuroprotection in ophthalmology
- •Endpoints
- •Neuroprotection and glaucoma
- •Conclusions
- •Abbreviations
- •References
- •Pathogenesis of ganglion ‘‘cell death’’ in glaucoma and neuroprotection: focus on ganglion cell axonal mitochondria
- •Introduction
- •Retinal ganglion cells and mitochondria
- •Possible causes for ganglion cell death in glaucoma
- •Mitochondrial functions and apoptosis
- •Mitochondrial function enhancement and the attenuation of ganglion cell death
- •Creatine
- •Nicotinamide
- •Epigallocatechin gallate
- •Conclusion
- •References
- •Astrocytes in glaucomatous optic neuropathy
- •Introduction
- •Quiescent astrocytes
- •Reactive astrocytes in glaucoma
- •Signal transduction in glaucomatous astrocytes
- •Protein tyrosine kinases (PTKs)
- •Serine/threonine protein mitogen-activated kinases (MAPKs)
- •G protein-coupled receptors
- •Ras superfamily of small G proteins
- •Astrocyte migration in the glaucomatous optic nerve head
- •Cell adhesion of ONH astrocytes
- •Connective tissue changes in the glaucomatous optic nerve head
- •Extracellular matrix synthesis by ONH astrocytes
- •Extracellular matrix degradation by reactive astrocytes
- •Oxidative stress in ONH astrocytes
- •Conclusions
- •Acknowledgments
- •References
- •Glaucoma as a neuropathy amenable to neuroprotection and immune manipulation
- •Glaucoma as a neurodegenerative disease
- •Oxidative stress and free radicals
- •Excessive glutamate, increased calcium levels, and excitotoxicity
- •Deprivation of neurotrophins and growth factors
- •Abnormal accumulation of proteins
- •Pharmacological neuroprotection for glaucoma
- •Protection of the retinal ganglion cells involves the immune system
- •Searching for an antigen for potential glaucoma therapy
- •Concluding remarks
- •References
- •Oxidative stress and glaucoma: injury in the anterior segment of the eye
- •Introduction
- •Oxidative stress
- •Trabecular meshwork
- •IOP increase and free radicals
- •Glaucomatous cascade
- •Nitric oxide and endothelins
- •Extracellular matrix
- •Metalloproteinases
- •Other factors of interest
- •Therapeutic and preventive substances of interest in glaucoma
- •Ginkgo biloba extract
- •Green tea
- •Ginseng
- •Memantine and its derivates
- •Conclusions
- •Abbreviations
- •References
- •Conclusions on neuroprotective treatment targets in glaucoma
- •Acknowledgments
- •References
- •Involvement of the Bcl2 gene family in the signaling and control of retinal ganglion cell death
- •Introduction
- •Intrinsic apoptosis vs. extrinsic apoptosis
- •The Bcl2 family of proteins
- •The requirement of BAX for RGC soma death
- •BH3-only proteins and the early signaling of ganglion cell apoptosis
- •Conclusion
- •Abbreviations
- •Acknowledgments
- •References
- •Assessment of neuroprotection in the retina with DARC
- •Introduction
- •DARC
- •Introducing the DARC technique
- •Annexin 5-labeled apoptosis and ophthalmoloscopy
- •Detection of RGC apoptosis in glaucoma-related animal models with DARC
- •Assessment of glutamate modulation with DARC
- •Glutamate at synaptic endings
- •Glutamate excitotoxicity in glaucoma
- •Assessment of coenzyme Q10 in glaucoma-related models with DARC
- •Summary
- •Abbreviations
- •Acknowledgment
- •References
- •Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection
- •Introduction
- •The endocannabinoid system in the eye
- •The IOP-lowering effects of endocannabinoids
- •Endocannabinoids and neuroprotection
- •Conclusions
- •References
- •Glaucoma of the brain: a disease model for the study of transsynaptic neural degeneration
- •Retinal ganglion cells, retino-geniculate neurons
- •Lateral geniculate nucleus
- •Mechanisms of RGC injury in glaucoma
- •Transsynaptic degeneration of the lateral geniculate nucleus in glaucoma
- •Neural degeneration in magno-, parvo-, and koniocellular LGN layers
- •Visual cortex in glaucoma
- •Neuropathology of glaucoma in the visual pathways in the human brain
- •Mechanisms of glaucoma damage in the central visual pathways
- •Implications of central visual system injury in glaucoma
- •Conclusion
- •Acknowledgments
- •References
- •Clinical relevance of optic neuropathy
- •Is there a remodeling of retinal circuitry?
- •Behavioral consequences of glaucoma
- •Glaucoma as a neurodegenerative disease versus neuroplasticity and adaptive changes
- •Future directions
- •Acknowledgment
- •References
- •Targeting excitotoxic/free radical signaling pathways for therapeutic intervention in glaucoma
- •Introduction
- •Channel properties of NMDA receptors correlated with excitotoxicity
- •Downstream signaling cascades after overactivation of NMDA receptors
- •Relevance of excitotoxicity to glaucoma
- •Therapeutic approaches to prevent RGC death by targeting the pathways involved in NMDA excitotoxicity
- •Drugs targeting NMDA receptors
- •Kinetics of NMDA receptor antagonists
- •Memantine
- •NitroMemantines
- •Drugs targeting downstream signaling molecules in NMDA-induced cell death pathways
- •p38 MAPK inhibitors
- •Averting caspase-mediated neurodegeneration
- •Abbreviations
- •Acknowledgments
- •References
- •Stem cells for neuroprotection in glaucoma
- •Introduction
- •Glaucoma as a model of neurodegenerative disease
- •Why use stem cells for neuroprotective therapy?
- •Stem cell sources
- •Neuroprotection by transplanted stem cells
- •Endogenous stem cells
- •Key challenges
- •Conclusion
- •Abbreviations
- •Acknowledgments
- •References
- •The relationship between neurotrophic factors and CaMKII in the death and survival of retinal ganglion cells
- •Introduction
- •Glaucoma and the RGCs
- •Are other retinal cells affected in glaucoma?
- •Retinal ischemia related glaucoma
- •Excitotoxicity and the retina
- •Signal transduction
- •NMDA receptor antagonists and CaMKII
- •Caspase-3 activation in NMDA-induced retinal cell death and its inhibition by m-AIP
- •BDNF and neuroprotection of RGCs
- •Summary and conclusions
- •Abbreviations
- •Acknowledgments
- •References
- •Evidence of the neuroprotective role of citicoline in glaucoma patients
- •Introduction
- •Patients: selection and recruitment criteria
- •Pharmacological treatment protocol
- •Methodology of visual function evaluation: electrophysiological examinations
- •PERG recordings
- •VEP recordings
- •Statistic evaluation of electrophysiological results
- •Electrophysiological (PERG and VEP) responses in OAG patients after the second period of evaluation
- •Effects of citicoline on retinal function in glaucoma patients: neurophysiological implications
- •Effects of citicoline on neural conduction along the visual pathways in glaucoma patients: neurophysiological implications
- •Possibility of neuroprotective role of citicoline in glaucoma patients
- •Conclusive remarks
- •Abbreviations
- •References
- •Neuroprotection: VEGF, IL-6, and clusterin: the dark side of the moon
- •Neuroprotection: VEGF-A, a shared growth factor
- •VEGF-A isoforms
- •VEGF-A receptors
- •Angiogenesis, mitogenesis, and endothelial survival
- •Neurotrophic and neuroprotective effect
- •Intravitreal VEGF inhibition therapy and neuroretina toxicity
- •Neuroprotection: clusterin, a multifunctional protein
- •Clusterin/ApoJ: a debated physiological role
- •Clusterin and diseases
- •Clusterin and the nervous system
- •Neuroprotection: IL-6, VEGF, clusterin, and glaucoma
- •Rational basis for the development of coenzyme Q10 as a neurotherapeutic agent for retinal protection
- •Introduction
- •Ischemia model
- •Neuroprotective effect of Coenzyme Q10 against cell loss yielded by transient ischemia in the RGC layer
- •Retinal ischemia and glutamate
- •Coenzyme Q10 minimizes glutamate increase induced by ischemia/reperfusion
- •Summary
- •Acknowledgment
- •References
- •17beta-Estradiol prevents retinal ganglion cell loss induced by acute rise of intraocular pressure in rat
- •Methods
- •Morphometric analysis
- •Microdialysis
- •Drug application
- •Statistical analysis
- •Results
- •17beta-Estradiol pretreatment minimizes RGC loss
- •Discussion
- •Acknowledgment
1998; Jampel et al., 2002; Nelson et al., 2003) and that our knowledge on visual field progression derives almost exclusively from SAP data.
Based on these considerations, it is still unrealistic to consider FDT and SWAP as diagnostic tools to be routinely used in clinical practice. A number of items, summarized in Table 4, need to be clarified in order to reconsider the role of unconventional perimetry in clinical practice. Nevertheless, the usefulness of both FDT and SWAP, at least in the subgroup of patients more at risk for developing the disease (i.e., patients with high intraocular pressure values, strong familiarity for glaucoma, severe vascular diseases), cannot be denied: their ability in anticipating by years the development of SAP abnormalities has been demonstrated (Ferreras et al., 2007; Leeprechanon et al., 2007) and is commonly ascertained by clinicians using these techniques. An example of this diagnostic ability is reported in Fig. 4, which shows the case of a patient with RNFL defects, normal SAP, and FDT and SWAP abnormalities at baseline, who developed glaucomatous defects at SAP 7 years later.
Considering that glaucoma still nowadays causes an unacceptably high number of visually impaired or even blind patients (Hattenhauer et al., 1998; Kwon et al., 2001; Oliver et al., 2002; Chen, 2003; Eid et al., 2003; Zahari et al., 2006; Forsman et al., 2007) and that motor vehicle accidents are significantly related to the level of SAP loss (McGwin et al., 1998; Szlyk et al., 2005; Haymes et al., 2007) in spite of patients being well within the legal visual requirements to hold a driving license and having only early field damage in the worse eye (Haymes et al., 2007), the possibility of adopting strategies to detect the earliest glaucoma defects and to prevent their evolution must be considered with extreme interest due to their possible positive effect on the socioeconomic impact of the disease.
References
Anderson, A.J. and Johnson, C.A. (2003) Frequency-doubling technology perimetry and optical defocus. Invest. Ophthalmol. Vis. Sci., 44: 4147–4152.
Artes, P.H., Hutchison, D.M., Nicolela, M.T., LeBlanc, R.P. and Chauhan, B.C. (2005) Threshold and variability
121
properties of matrix frequency-doubling technology and standard automated perimetry in glaucoma. Invest. Ophthalmol. Vis. Sci., 46: 2451–2457.
Artes, P.H., Nicolela, M.T., McCormick, T.A., LeBlanc, R.P. and Chauhan, B.C. (2003) Effects of blur and repeated testing on sensitivity estimates with frequency doubling perimetry. Invest. Ophthalmol. Vis. Sci., 44: 646–652.
Bagga, H., Feuer, W.J. and Greenfield, D.S. (2006) Detection of psychophysical and structural injury in eyes with glaucomatous optic neuropathy and normal standard automated perimetry. Arch. Ophthalmol., 124: 169–176.
Bayer, A.U. and Erb, C. (2002) Short wavelength automated perimetry, frequency doubling technology perimetry, and pattern electroretinography for prediction of progressive glaucomatous standard visual field defects. Ophthalmology, 109: 1009–1017.
Bayer, A.U., Maag, K.P. and Erb, C. (2002) Detection of optic neuropathy in glaucomatous eyes with normal standard visual fields using a test battery of short-wavelength automated perimetry and pattern electroretinography. Ophthalmology, 109: 1350–1361.
Bengtsson, B. and Heijl, A. (2003) Normal intersubject threshold variability and normal limits of the SITA SWAP and full threshold SWAP perimetric programs. Invest. Ophthalmol. Vis. Sci., 44: 5029–5034.
Bengtsson, B. and Heijl, A. (2006) Diagnostic sensitivity of fast blue-yellow and standard automated perimetry in early glaucoma: a comparison between different test programs. Ophthalmology, 13(7): 1092–1097.
Blumenthal, E.Z., Haddad, A., Horani, A. and Anteby, I. (2004) The reliability of frequency-doubling perimetry in young children. Ophthalmology, 111: 435–439.
Blumenthal, E.Z., Sample, P.A., Berry, C.C., Lee, A.C., Girkin, C.A., Zangwill, L., Caprioli, J. and Weinreb, R.N. (2003) Evaluating several sources of variability for standard and SWAP visual fields in glaucoma patients, suspects, and normals. Ophthalmology, 110: 1895–1902.
Bowd, C., Zangwill, L.M., Berry, C.C., Blumenthal, E.Z., Vasile, C., Sanchez-Galeana, C., Bosworth, C.F., Sample, P.A. and Weinreb, R.N. (2001) Detecting early glaucoma by assessment of retinal nerve fiber layer thickness and visual function. Invest. Ophthalmol. Vis. Sci., 42(9): 1993–2003.
Brush, M.B. and Chen, P.P. (2004) Learning effect among perimetric novices with screening C-20-1 frequency doubling technology perimetry. Am. J. Ophthalmol., 137: 551–552.
Brusini, P. (2006) Frequency doubling technology staging system 2. J. Glaucoma, 15: 315–320.
Brusini, P. and Tosoni, C. (2003) Staging of functional damage in glaucoma using frequency doubling technology. J. Glaucoma, 12(5): 417–426.
Brusini, P., Salvetat, M.L., Zeppieri, M. and Parisi, L. (2006a) Frequency doubling technology perimetry with the Humphrey Matrix 30-2 test. J. Glaucoma, 15: 77–83.
Brusini, P., Salvetat, M.L., Zeppieri, M., Tosoni, C., Parisi, L. and Felletti, M. (2006b) Visual field testing with the new Humphrey Matrix: a comparison between the FDT N-30 and Matrix N-30-F tests. Acta Ophthalmol. Scand., 84: 351–356.
Burgansky-Eliash, Z., Wollstein, G., Patel, A., Bilonick, R.A., Ishikawa, H., Kagemann, L., Dilworth, W.D. and Schuman,
122
J.S. (2007) Glaucoma detection with matrix and standard achromatic perimetry. Br. J. Ophthalmol., 91: 933–938.
Callaway, E.M. (2005) Structure and function of parallel pathways in the primate early visual system. J. Physiol., 566(Pt 1): 13–19.
Canadian Glaucoma Study: 1. (2006) Study design, baseline characteristics, and preliminary analyses. The Canadian Glaucoma Study Group. Can. J. Ophthalmol., 41: 566–575.
Chen, P.P. (2003) Blindness in patients with treated open-angle glaucoma. Ophthalmology, 110: 726–733.
Collaborative Normal-Tension Glaucoma Study Group. (1998) Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am. J. Ophthalmol., 126: 487–497.
Contestabile, M.T., Perdicchi, A., Amodeo, S., Recupero, V. and Recupero, S.M. (2007) The influence of learning effect on frequency doubling technology perimetry (Matrix). J. Glaucoma, 16: 297–301.
Dacey, D.M. and Lee, B.B. (1994) The ‘‘blue-on’’ opponent pathway in primate retina originates from a distinct bistratified ganglion cell type. Nature, 367: 731–735.
Delgado, M.F., Nguyen, N.T., Cox, T.A., Singh, K., Lee, D.A., Dueker, D.K., Fechtner, R.D., Juzych, M.S., Lin, S.C., Netland, P.A., Pastor, S.A., Schuman, J.S. and Samples, J.R. (2002) Automated perimetry: a report by the American Academy of Ophthalmology. Ophthalmology, 109: 2362–2374.
DeMonasterio, F.M. (1979) Asymmetry of onand offpathways of blue-sensitive cones of the retina of macaque. Brain Res., 166: 39–48.
Dobkins, K.R. and Albright, T.D. (2004) Merging processing streams: colour clues for motion detection and interpretation. In: Chalupa L.M. and Werner J.S. (Eds.), The Visual Neurosciences. The MIT Press, Cambridge, MA, pp. 1217–1228.
Drance, S.M., Lakowski, R., Schulzer, M. and Douglas, G.R. (1981) Acquired colour vision changes in glaucoma: use of 100-Hue Test and Pickford anomaloscope as predictors of glaucomatous field change. Arch. Ophthalmol., 99: 829–831.
Eid, T.M., Spaeth, G.L., Bitterman, A. and Steinmann, W.C. (2003) Rate and amount of visual loss in 102 patients with open-angle glaucoma followed up for at least 15 years. Ophthalmology, 110: 900–907.
Eisner, A., Toomey, M.D., Incognito, L.J., O’Malley, J.P. and Samples, J.R. (2006) Contrasting blue-on-yellow with white- on-white visual fields: roles of visual adaptation for healthy perior postmenopausal women younger than 70 years of age. Invest. Ophthalmol. Vis. Sci., 47: 5605–5614.
Ferreras, A., Polo, V., Larrosa, J.M., Pablo, L.E., Pajarin, A.B., Pueyo, V. and Honrubia, F.M. (2007) Can frequency-doubling technology and short-wavelength automated perimetries detect visual field defects before standard automated perimetry in patients with preperimetric glaucoma? J. Glaucoma, 16: 372–383.
Fogagnolo, P., Mazzolani, F., Rossetti, L. and Orzalesi, N. (2005) Detecting glaucoma with frequency-doubling
technology perimetry a comparison between N-30 and C-20 screening programs. J. Glaucoma, 14: 485–491.
Forsman, E., Kivela, T. and Vesti, E. (2007) Lifetime visual disability in open-angle glaucoma and ocular hypertension. J. Glaucoma, 16: 313–319.
Friedman, D.S., Nordstrom, B., Mozaffari, E. and Quigley, H.A. (2005) Glaucoma management among individuals enrolled in a single comprehensive insurance plan. Ophthalmology, 112: 1500–1504.
Gardiner, S.K., Anderson, D.R., Fingeret, M., McSoley, J.J. and Johnson, C.A. (2006) Evaluation of decision rules for frequency-doubling technology screening tests. Optom. Vis. Sci., 83: 432–437.
Girkin, C.A., Emdadi, A., Sample, P.A., Blumenthal, E.Z., Lee, A.C., Zangwill, L.M. and Weinreb, R.N. (2000) Shortwavelength automated perimetry and standard perimetry in the detection of progressive optic disc cupping. Arch. Ophthalmol., 118: 1231–1236.
Gordon, M.O. and Kass, M.A. (1999) The ocular hypertension treatment study: design and baseline description of the participants. Arch. Ophthalmol., 117: 573–583.
Gupta, N. and Yucel, Y.H. (2007) What changes can we expect in the brain of glaucoma patients?. Surv. Ophthalmol., 52(suppl 2): S122–S126.
Gutierrez, P., Wilson, M.R., Johnson, C., Gordon, M., Cioffi, G.A. and Ritch, R. (1997) Influence of glaucomatous visual field loss on health-related quality of life. Arch. Ophthalmol., 115: 777–784.
Hartline, H.K. (1940) The receptive fields of optic nerve fibers. Am. J. Physiol., 130: 700–711.
Harwerth, R.S., Carter-Dawson, L. and Shen, F. (1999) Ganglion cell losses underlying visual field defects from experimental glaucoma. Invest. Ophthalmol. Vis. Sci., 40: 2242–2250.
Hattenhauer, M.G., Johnson, D.H., Ing, H.H., Herman, D.C., Hodge, D.O. and Yawn, B.P. (1998) The probability of blindness from open-angle glaucoma. Ophthalmology, 105: 2099–2104.
Haymes, D., Hutchison, D.M., McCormick, T.A., Varma, D.K., Nicolela, M.T., LeBlanc, R.P. and Chauhan, B.C. (2005) Glaucomatous visual field progression with frequencydoubling technology and standard automated perimetry in a longitudinal prospective study. Invest. Ophthalmol. Vis. Sci., 46: 547–554.
Haymes, S.A., Leblanc, R.P., Nicolela, M.T., Chiasson, L.A. and Chauhan, B.C. (2007) Risk of falls and motor vehicle collisions in glaucoma. Invest. Ophthalmol. Vis. Sci., 48: 1149–1155.
Hodapp, E., Parrish II, R. and Anderson, D. (1993) Clinical Decisions in Glaucoma. CV Mosby, St Louis, pp. 11–63.
Horn, F.K., Brenning, A., Ju¨nemann, A.G. and Lausen, B. (2007) Glaucoma detection with frequency doubling perimetry and short-wavelength perimetry. J. Glaucoma, 16: 363–371.
Horn, F.K., Nguyen, N.X., Mardin, C.Y. and Ju¨nemann, A.G. (2003) Combined use of frequency doubling perimetry and polarimetric measurements of retinal nerve fiber layer in glaucoma detection. Am. J. Ophthalmol., 135: 160–168.
Hosking, S.L. and Hilton, E.J. (2002) Neurotoxic effects of GABA-transaminase inhibitors in the treatment of epilepsy: ocular perfusion and visual performance. Ophthalmic. Physiol. Opt., 22(5): 440–447.
Hubel, D.H. and Wiesel, T.N. (1959) Receptive fields of single neurons in the cat’s striate cortex. J. Physiol., 148: 574–591.
Hutchings, N., Hosking, S.L., John, M. and Flanagan, J.G. (2001) Long-term fluctuation in short wavelength automated perimetry in glaucoma suspects and glaucoma patients. Invest. Ophthalmol. Vis. Sci., 42: 2332–2337.
Jampel, H.D., Friedman, D.S., Quigley, H. and Miller, R. (2002) Correlation of the binocular visual field with patient assessment of vision. Invest. Ophthalmol. Vis. Sci., 43: 1059–1067.
Johnson, C.A. (1994) Selective versus nonselective losses in glaucoma. J. Glaucoma, 3(suppl 1): 32–44.
Johnson, C.A. and Samuels, S.J. (1997) Screening for glaucomatous visual field loss with frequency-doubling perimetry. Invest. Ophthalmol. Vis. Sci., 38: 413–425.
Johnson, C.A., Adams, A.J., Casson, E.J. and Brandt, J.D. (1993a) Blue-on-yellow perimetry can predict the development of glaucomatous visual field loss. Arch. Ophthalmol., 111: 645–650.
Johnson, C.A., Adams, A.J., Casson, E.J. and Brandt, J.D. (1993b) Progression of early glaucomatous visual field loss for blue-on-yellow and standard white-on-white automated perimetry. Arch. Ophthalmol., 111: 651–656.
Johnson, C.A., Sample, P.A., Cioffi, G.A., Liebmann, J.R. and Weinreb, R.N. (2002) Structure and function evaluation (SAFE): I. criteria for glaucomatous visual field loss using standard automated perimetry (SAP) and short wavelength automated perimetry (SWAP). Am. J. Ophthalmol., 134: 177–185.
Kaplan, E. (2004) The M, P, K pathways of the primate visual system. In: Chalupa L.M. and Werner J.S. (Eds.), The Visual Neurosciences. The MIT Press, Cambridge, MA, pp. 481–493.
Kelly, D.H. (1966) Frequency doubling in visual responses. J. Opt. Soc. Am., 56: 1628–1633.
Keltner, J.L. and Johnson, C.A. (1995) Short-wavelength automated perimetry in neuro-ophthalmologic disorders. Arch. Ophthalmol., 113(4): 475–481.
Kim, T.W., Zangwill, L.M., Bowd, C., Sample, P.A., Shah, N. and Weinreb, R.N. (2007) Retinal nerve fiber layer damage as assessed by optical coherence tomography in eyes with a visual field defect detected by frequency doubling technology perimetry but not by standard automated perimetry. Ophthalmology, 114: 1053–1057.
Kuffler, S.W. (1953) Discharge patterns and functional organization of mammalian retina. J. Neurophysiol., 16: 37–68.
Kwon, Y.H., Kim, C.S., Zimmerman, M.B., Alward, W.L. and Hayreh, S.S. (2001) Rate of visual field loss and long-term visual outcome in primary open-angle glaucoma. Am. J. Ophthalmol., 132: 47–56.
Landers, J.A., Goldberg, I.F. and Graham, S.L. (2003) Detection of early visual field loss in glaucoma using
123
frequency-doubling perimetry and short-wavelength automated perimetry. Arch. Ophthalmol., 121: 1705–1710.
Landers, J., Sharma, A., Goldberg, I. and Graham, S. (2006) Topography of the frequency doubling perimetry visual field compared with that of short wavelength and achromatic automated perimetry visual fields. Br. J. Ophthalmol., 90: 70–74.
Lee, M.J., Kim, D.M., Jeoung, J.W., Hwang, S.S., Kim, T.W. and Park, K.H. (2007) Localized retinal nerve fiber layer defects and visual field abnormalities by Humphrey Matrix frequency doubling technology perimetry. Am. J. Ophthalmol., 143: 1056–1058.
Leeprechanon, N., Giaconi, J.A., Manassakorn, A., Hoffman, D. and Caprioli, J. (2007) Frequency doubling perimetry and short-wavelength automated perimetry to detect early glaucoma. Ophthalmology, 114: 931–937.
Leske, M.C., Heijl, A., Hyman, L. and Bengtsson, B. (1999) Early manifest glaucoma trial: design and baseline data. Ophthalmology, 106: 2144–2153.
Maddess, T. and Henry, G.H. (1992) Performance of nonlinear visual units in ocular hypertension and glaucoma. Clin. Vis. Sci., 7: 371–383.
McGwin, G., Jr., Owsley, C. and Ball, K. (1998) Identifying crash involvement among older drivers: agreement between self-report and state records. Accid. Anal. Prev., 30: 781–791.
McKendrick, A.M., Cioffi, G.A. and Johnson, C.A. (2002) Short-wavelength sensitivity deficits in patients with migraine. Arch. Ophthalmol., 120(2): 154–161.
Mok, K.H., Lee, V.W. and So, K.F. (2003) Retinal nerve fiber layer measurement by optical coherence tomography in glaucoma suspects with short-wavelength perimetry abnormalities. J. Glaucoma, 12: 45–49.
Musch, D.C., Lichter, P.R., Guire, K.E. and Standardi, C.L. (1999) The collaborative initial glaucoma treatment study: study design, methods, and baseline characteristics of enrolled patients. Ophthalmology, 106: 653–662.
Nelson, P., Aspinall, P., Papasouliotis, O., Worton, B. and O’Brien, C. (2003) Quality of life in glaucoma and its relationship with visual function. J. Glaucoma, 12: 139–150.
Oliver, J.E., Hattenhauer, M.G., Herman, D., Hodge, D.O., Kennedy, R. and Fang-Yen, M. (2002) Blindness and glaucoma: a comparison of patients progressing to blindness from glaucoma with patients maintaining vision. Am. J. Ophthalmol., 133: 764–772.
Paczka, J.A., Friedman, D.S., Quigley, H.A., Barron, Y. and Vitale, S. (2001) Diagnostic capabilities of frequency-dou- bling tecnology, scanning laser polarimetry and nerve fiber layer photograph to distinguish glaucomatous damage. Am. J. Ophthalmol., 131: 188–197.
Parrish, R.K., 2nd, Gedde, S.J., Scott, I.U., Feuer, W.J., Schiffman, J.C. and Mangione, C.M. (1997) Visual function and quality of life among patients with glaucoma. Arch. Ophthalmol., 115: 1447–1455.
Polo, V., Abecia, E., Pablo, L.E., Pinilla, I., Larrosa, J.M. and Honrubia, F.M. (1998) Short-wavelength automated perimetry and retinal nerve fiber layer evaluation in suspected cases of glaucoma. Arch. Ophthalmol., 116: 1295–1298.
124
Polo, V., Larrosa, J.M., Pinilla, I., Pablo, L. and Honrubia, F.M. (2001) Optimum criteria for short-wavelength automated perimetry. Ophthalmology, 108: 285–289.
Polo, V., Larrosa, J.M., Pinilla, I., Perez, S., Gonzalvo, F. and Honrubia, F.M. (2002) Predictive value of short-wavelength automated perimetry: a 3-year follow-up study. Ophthalmology, 109: 761–765.
Polyak, S.L. (1941) The Retina. University of Chicago Press, Chicago.
Remky, A., Arend, O. and Hendricks, S. (2000) Shortwavelength automated perimetry and capillary density in early diabetic maculopathy. Invest. Ophthalmol. Vis. Sci., 41(1): 274–281.
Reus, N.J., Colen, T.P. and Lemij, H.G. (2005) The prevalence of glaucomatous defects with short-wavelength automated perimetry in patients with elevated intraocular pressures. J. Glaucoma, 14: 26–29.
Rossetti, L., Fogagnolo, P., Miglior, S., Centofanti, M., Vetrugno, M. and Orzatesi, N. (2006) Learning effect of short-wavelength automated perimetry in patients with ocular hypertension. J. Glaucoma, 15(5): 399–404.
Sample, P.A., Bosworth, C.F., Blumenthal, E.Z., Girkin, C. and Weinreb, R.N. (2000a) Visual function specific perimetry for indirect comparison of different ganglion cell populations in glaucoma. Invest. Ophthalmol. Vis. Sci., 41: 1783–1790.
Sample, P.A., Bosworth, C.F. and Weinreb, R.N. (2000b) The loss of visual function in glaucoma. Semin. Ophthalmol., 15: 182–193.
Sample, P.A., Johnson, C.A., Haegerstrom-Portnoy, G. and Adams, A.J. (1996) Optimum parameters for short-wave- length automated perimetry. J. Glaucoma, 5: 375–383.
Sample, P.A., Medeiros, F.A., Racette, L., Pascual, J.P., Boden, C., Zangwill, L.M., Bowd, C. and Weinreb, R.N. (2006) Identifying glaucomatous vision loss with visual- function–specific perimetry in the diagnostic innovations in glaucoma study. Invest. Ophthalmol. Vis. Sci., 47: 3381–3389.
Sa´nchez-Galeana, C.A., Bowd, C., Zangwill, L.M., Sample, P.A. and Weinreb, R.N. (2004) Short-wavelength automated perimetry results are correlated with optical coherence tomography retinal nerve fiber layer thickness measurements in glaucomatous eyes. Ophthalmology, 111: 1866–1872.
Shah, N.N., Bowd, C., Medeiros, F.A., Weinreb, R.N., Sample, P.A., Hoffmann, E.M. and Zangwill, L.M. (2007) Combining structural and functional testing for detection of glaucoma. Ophthalmology, 114: p. 1414.
Sherwood, M.B., Garcia-Siekavizza, A., Meltzer, M.I., Hebert, A., Burns, A.F. and McGorray, S. (1998) Glaucoma’s impact on quality of life and its relation to clinical indicators. A pilot study. Ophthalmology, 105: 561–566.
Soliman, M.A., De Jong, L.A., Ismaeil, A.A., Van den Berg, T.J. and De Smet, M.D. (2002) Standard achromatic perimetry, short wavelength automated perimetry, and frequency doubling technology for detection of glaucoma damage. Ophthalmology, 109: 444–454.
Solomon, S.G., Barry, B.L., Andrew, J.R., White, L.R. and Martin, P.R. (2005) Chromatic organization of ganglion cell receptive fields in the peripheral retina. J. Neurosci., 25: 4527–4539.
Solomon, S.G., White, A.J.R. and Martin, P.R. (2002) Extraclassical receptive fields in primate LGNJ. Neurosci., 22(1): 338–349
Spry, P.G., Hussin, H.M. and Sparrow, J.M. (2005) Glaucoma detection with matrix and standard achromatic perimetry. Br. J. Ophthalmol., 91: 933–938.
Spry, P.G., Hussin, H.M. and Sparrow, J.M. (2007) Performance of the 24-2-5 frequency doubling technology screening test: a prospective case study. Br. J. Ophthalmol., 91: 1345–1349.
Szlyk, J.P., Mahler, C.L., Seiple, W., Edward, D.P. and Wilensky, J.T. (2005) Driving performance of glaucoma patients correlates with peripheral visual field loss. J. Glaucoma, 14: 145–150.
The Advanced Glaucoma Intervention Study (AGIS) 1. (1994) Study design and methods and baseline characteristics of study patients. Control Clin. Trials, 15: 299–325.
To´th, M., Ko´thy, P., Vargha, P. and Hollo´, G. (2007) Accuracy of combined GDx-VCC and matrix FDT in a glaucoma screening trial. J. Glaucoma, 16: 462–470.
Trible, J.R., Schultz, R.O., Robinson, J.C. and Rothe, T.L. (2000) Accuracy of glaucoma detection with frequencydoubling perimetry. Am. J. Ophthalmol., 129: 740–745.
Tyrell, R.A. and Owens, D.A. (1998) A rapid technique to assess the resting states of the eyes and other threshold phenomena: The Modified Binary Search (MOBS). Behav. Res. Methods Instr. Computers, 20: 137–141.
Weinreb, R.N., Lindsey, J.D. and Sample, P.A. (1994) Lateral geniculate nucleus in glaucoma. Am. J. Ophthalmol., 118: 126–129.
White, A.J., Sun, H., Swanson, W.H. and Lee, B.B. (2002) An examination of physiological mechanisms underlying the frequency-doubling illusion. Invest. Ophthalmol. Vis. Sci., 43: 3590–3599.
Wild, J.M., Cubbidge, R.P., Pacey, I.E. and Robinson, R. (1998) Statistical aspects of the normal visual field in shortwavelength automated perimetry. Invest. Ophthalmol. Vis. Sci., 39(1): 54–63.
Wild, J.M., Kim, L.S., Pacey, I.E. and Cunliffe, I.A. (2006) Evidence for a learning effect in short-wavelength automated perimetry. Ophthalmology, 113(2): 206–215.
Yucel, Y.H., Zhang, Q., Weinreb, R.N., Kaufman, P.L. and Gupta, N. (2003) Effects of retinal ganglion cell loss on magno-, parvo-, koniocellular pathways in the lateral geniculate nucleus and visual cortex in glaucoma. Prog. Retin. Eye Res., 22(4): 465–481.
Zahari, M., Mukesh, B.N., Rait, J.L., Taylor, H.R. and McCarty, C.A. (2006) Progression of visual field loss in open angle glaucoma in the Melbourne Visual Impairment Project. Clin. Experiment Ophthalmol., 34: 20–26.
Zangwil, L.M.L., Bowd, C. and Weinreb, R.N. (2006) Identifying glaucomatous vision loss with visual-function– specific perimetry in the diagnostic innovations in glaucoma study. Invest. Ophthalmol. Vis. Sci., 47: 3381–3389.